Skip to main content
SHTDY logo

Sinopharm Group Co. Ltd. (SHTDY) Stock Price & Analysis

Sinopharm Group Co. Ltd. (SHTDY) — price $10.62 (-0.75%), as of the Nov 20, 2026 trading session; market cap $6.63B.

Educational signal · not a buy or sell recommendation · How to read this

$10.62 −$0.08 (-0.75%) Market Cap $6.63B

Sinopharm Group Co. Ltd. · SHTDY · Healthcare · Medical - Distribution

Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products.

Price as of Nov 20, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • HSIC · Henry Schein, Inc. · 73 /100
  • GRDN · Guardian Pharmacy Services, Inc. · 96 /100
  • PBH · Prestige Consumer Healthcare Inc. · 63 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$10.62
Change on the day-0.75%
52-week range$9.00–$14.87
Market capitalisation$6.63B—
Price / earnings (trailing)6.38
Shares traded on the day13.5K
Beta (volatility vs the S&P 500)0.45

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $9.36, high $14, latest $11. $14 $9.36 high $14 Oct 17, 2025 Nov 20, 2026 · $11 $12Oct 17, 2025$12Oct 31, 2025$14Nov 14, 2025$13Nov 28, 2025$13Dec 12, 2025$13Dec 26, 2025$13Jan 9, 2026$13Jan 23, 2026$14Feb 6, 2026$13Feb 20, 2026$13Mar 6, 2026$13Mar 20, 2026$13Apr 2, 2026$13Apr 17, 2026$12May 1, 2026$11May 15, 2026$11May 29, 2026$11Jun 12, 2026$10Jun 26, 2026$11Jul 10, 2026$11Jul 24, 2026$11Aug 7, 2026$11Aug 21, 2026$9.91Sep 4, 2026$9.44Sep 18, 2026$9.36Oct 2, 2026$9.98Oct 16, 2026$10Oct 30, 2026$11Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Sinopharm Group Co. (SHTDY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Neutral
ROE Neutral
Gross Margin Negative

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 19, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Sinopharm Group Co. (SHTDY), and what does it report?

Short answer

Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. Healthcare / Medical Distribution Headquarters: Sinopharm Group Building, Shanghai, SH, 200023, CN. It employs 94,910 people and is led by Wanyong Lian. In Q2 FY2026 it reported revenue of CN¥279.68B and net income of CN¥3.37B. The market values it at $6.63B.

2 · Latest results

What do the latest results show for Sinopharm Group Co. (SHTDY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of CN¥279.68B.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026CN¥279.68BCN¥3.37BCN¥5.35 (diluted)
Q4 FY2025CN¥283.78BCN¥3.62BCN¥5.80 (diluted)
Q2 FY2025CN¥286.04BCN¥3.46BCN¥5.55 (diluted)
Q4 FY2024CN¥289.78BCN¥3.35BCN¥5.35 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Sinopharm Group Co. (SHTDY)?

Short answer

The distress and quality screens read Altman Z 2.15 · Piotroski F 6. Trailing ratios: ROE 8.0% · ROA 2.6% · current ratio 1.41.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SHTDY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SHTDY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About SHTDY (Healthcare)

Research dated 2026-09-13; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.

What do fundamental quality screens indicate about earnings sustainability?

Standard financial solvency screens like the Piotroski F-score and Altman Z-score indicate that Sinopharm faces low bankruptcy risk and maintains adequate balance-sheet quality. However, these screens measure financial solvency, not the sustainability of operating margins, which depends on competitive and regulatory factors that balance sheets do not capture.

What is the SHTDY stock price today?

The last price recorded for Sinopharm Group Co. Ltd. (SHTDY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 15 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • FAQ: What do fundamental quality screens indicate about earnings sustainability?: Distress and quality screens; Reported versus estimated, last 8 quarters; Trailing twelve-month ratio set
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.